Over the next year, the Company anticipates a requirement of about $1.5 million to maintain current operating activities and from approximately $2 million to $5 million to fund: (1) the FDA approval process and initial deployment of the brachytherapy products, and (2) a sales capability for third party isotopes and equipment
The Company anticipates funding the initial six months of its requirements for brachytherapy, sales agency activities and potentially the acquisition of a controlling interest in the German company through the sale of equity or equity-linked securities.
The acquisition of a controlling interest in the German company likely would require up to approximately $3 million of cash and stock. Following its acquisition, the target company should operate on a cash positive basis. In allocating its capital between the brachytherapy products and the potential acquisition, the Company's first priority is the FDA clearance for, and successful roll-out of, the brachytherapy products. The Company believes that its acquisition of a controlling interest in the German target company would help achieve that goal in Europe and Russia.
My guess is they hope for a pop in the stock price after the FDA gives them the approval before they have to do a massive dilution to buy the German company otherwise we are looking at the 20-300mill share dilution to stay alive another year w/o Dr Bob keeping us in the good graces of Battelle. What they give us now is chicken feed compared to in the prior yrs when he was alive and pumping out the patents etc. If they do this merger under the 2-3 cent a stock price it will surely be only a matter of time before the dreaded Reverse stock split happens with at least a 5-10 to 1 reverse to make us somewhat credible depending on the going price of the day a yr from now or so.